PR Newswire
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
📈
AI Sentiment
Highly Positive
8/10
Neurocrine Biosciences Inc. News
Latest updates and market news for NBIX
1 news
Jan 24 - Jan 30, 2026
Page 1
Share this news page